Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/39005
Title: Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial
Authors: Ono, Masafumi
Hara, Hironori
Kawashima, Hideyuki
Gao, Chao
Wang , Rutao
Wykrzykowska, Joanna J.
Piek, Jan J.
Garg, Scot
Hamm, Christian
Steg, Philippe Gabriel
Valgimigli, Marco
Windecker, Stephan
VRANCKX, Pascal 
Onuma, Yoshinobu
Serruys, Patrick W.
Issue Date: 2022
Publisher: EUROPA EDITION
Source: EuroIntervention, 18 (5) , p. E377 -+
Abstract: Background: The optimal antiplatelet strategy in the second year after percutaneous coronary intervention (PCI) remains unclear. Aims: We aimed to compare ticagrelor monotherapy with aspirin monotherapy on clinical outcomes be and 1 year post-PCI. Methods: This post hoc subanalysis of the open-label, all-corners, randomised GLOBAL LEADERS trial, which con pared 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT) with 12-month aspirin monotherapy following 12-month DAPT, only included patients who, at 12 months, were free from ischaemic and bleeding events and were adherent to their assigned antiplatelet therapy. The incidences of ischaemic events (all-cause death, any myocardial infarction, or any stroke) and bleeding events (Bleeding Academic Research Consortium [BARC] type 3 or 5 bleeding) during the second year (12-24 months) were compared between patients receiving either ticagrelor or aspirin monotherapy. Results: The present analysis included 11,121 (ticagrelor monotherapy n=5,308, and aspirin monotherapy n=5,813) of the 15,991 patients enrolled in GLOBAL LEADERS. During the second year, the ischaemic composite endpoint was lower with ticagrelor monotherapy compared to aspirin monotherapy (1.9% vs 2.6%: log-rank p=0.014, adjusted hazard ratio [BR] 0.74, 95% confidence interval [CI]: 0.58-0.96; p=0.022), which was primarily driven by a reduced risk of myocardial infarction. In contrast, BARC type 3 or 5 bleeding was numerically higher with ticagrelor monotherapy (0.5% vs 0.3%: log-rank - 0.051, adjusted HR 1.89, 95% CI: 1.03-3.45; p=0.005). Conclusions: Patients free from events at the end of the first year post-PCI and who adhered to their prescribed regimen had a reduced risk of ischaemic events compared to aspirin monotherapy in the second year post-PCI.
Notes: Serruys, PW (corresponding author), Natl Univ Ireland, Dept Cardiol, Univ Rd, Galway H91 TK33, Ireland.
pairick.serruys@nuigalway.ie
Keywords: ACS/NSTE-ACS;adjunctive pharmacotherapy;drug-eluting stentst;able angina
Document URI: http://hdl.handle.net/1942/39005
ISSN: 1774-024X
e-ISSN: 1969-6213
DOI: 10.4244/EIJ-D-21-00870
ISI #: 000882974700005
Rights: Europa Digital & Publishing 2022. All rights reserved.
Category: A1
Type: Journal Contribution
Validations: ecoom 2023
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Ticagrelor monotherapy.pdf
  Restricted Access
Peer-reviewed author version1.63 MBAdobe PDFView/Open    Request a copy
ticagrelor_monotherapy_versus_aspirin_monotherapy_at_12_months_after_percutaneou.pdf
  Restricted Access
Published version690.98 kBAdobe PDFView/Open    Request a copy
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.